Decrease in alpha-1 antiproteinase antitrypsin is observed in primary Sjogren's syndrome condition by Singh, Brij B. et al.
 
 
 University of Groningen
Decrease in alpha-1 antiproteinase antitrypsin is observed in primary Sjogren's syndrome
condition
Singh, Brij B.; Ohm, Joyce; Zanbede, Fredice O. Quenum; Chauhan, Pooja; Kroese, Frans G.





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2020
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Singh, B. B., Ohm, J., Zanbede, F. O. Q., Chauhan, P., Kroese, F. G. M., Vissink, A., Ambrus, J. L., &
Mishra, B. B. (2020). Decrease in alpha-1 antiproteinase antitrypsin is observed in primary Sjogren's
syndrome condition. Autoimmunity, 53(5), 270-282. https://doi.org/10.1080/08916934.2020.1768376
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 26-12-2020
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=iaut20
Autoimmunity
ISSN: 0891-6934 (Print) 1607-842X (Online) Journal homepage: https://www.tandfonline.com/loi/iaut20
Decrease in alpha-1 antiproteinase antitrypsin is
observed in primary Sjogren’s syndrome condition
Brij B. Singh, Joyce Ohm, Fredice O. Quenum Zanbede, Pooja Chauhan, Frans
G. M. Kroese, Arjan Vissink, Julian L. Ambrus & Bibhuti B. Mishra
To cite this article: Brij B. Singh, Joyce Ohm, Fredice O. Quenum Zanbede, Pooja Chauhan,
Frans G. M. Kroese, Arjan Vissink, Julian L. Ambrus & Bibhuti B. Mishra (2020) Decrease
in alpha-1 antiproteinase antitrypsin is observed in primary Sjogren’s syndrome condition,
Autoimmunity, 53:5, 270-282, DOI: 10.1080/08916934.2020.1768376
To link to this article:  https://doi.org/10.1080/08916934.2020.1768376
© 2020 The Author(s). Published by Informa
UK Limited, trading as Taylor & Francis
Group.
Published online: 25 May 2020.
Submit your article to this journal 
Article views: 427
View related articles 
View Crossmark data
ORIGINAL ARTICLE
Decrease in alpha-1 antiproteinase antitrypsin is observed in primary Sjogren’s
syndrome condition
Brij B. Singha,b , Joyce Ohmb, Fredice O. Quenum Zanbedeb, Pooja Chauhanb, Frans G. M. Kroesec, Arjan
Vissinkd, Julian L. Ambruse and Bibhuti B. Mishraa,b
aDepartment of Periodontics, School of Dentistry University of Texas Health Science Center, San Antonio, TX, USA; bDepartment of
Biomedical Sciences, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, ND, USA; cDepartment of
Rheumatology and Clinical Immunology, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands;
dDepartment of Oral and Maxillofacial Surgery, University of Groningen and University Medical Center Groningen, Groningen, The
Netherlands; eDivision of Allergy, Immunology, and Rheumatology, Department of Medicine, School of Medicine and Biomedical Sciences,
State University of New York, Buffalo, NY, USA
ABSTRACT
Primary Sjogren’s syndrome (pSS) is a systemic autoimmune disease that is characterized by the infil-
tration of immune cells. Although the loss of salivary gland function is a major manifestation observed
in pSS, the factors that could promote these changes in salivary gland tissue in pSS is not yet deter-
mined. Herein, we provide evidence that loss of alpha-1 antiproteinase antitrypsin could contribute to
the induction of pSS. Alpha-1 antiproteinase antitrypsin belongs to the family of serpin proteins that
function as protease inhibitors and protect secretory cells against proteases, especially to elastases
that is secreted from lymphocytes. Importantly, expression of alpha-1 antiproteinase antitrypsin was
decreased (more than 3-fold), along with an increase in elastase expression, in pSS samples when
compared with age-matched non-SS-SICCA patients. Consistent with the human data, loss of alpha-1
antiproteinase antitrypsin, as well as an increase in immune infiltration, was observed in IL14a trans-
genic mice that exhibit SS like symptoms. Moreover, an age-dependent increase in elastase expression
was observed in IL14a transgenic mice along with a decrease in total saliva secretion. Importantly, a
4-fold increase in microRNA132 expression, but not in other microRNAs, and increased DNA methyla-
tion in the promoter/noncoding region of serpina gene was observed in pSS, which could be respon-
sible for the inhibition of alpha-1 antiproteinase antitrypsin expression in salivary gland cells of pSS
patients. Together, these findings demonstrate that epigenetic regulations that include DNA methyla-
tion and microRNAs that could modulate the expression of alpha-1 antiproteinase antitrypsin in saliv-
ary glands and could be involved in the onset of pSS.
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Primary Sjogren’s syndrome (pSS) is a complex autoimmune
disorder that affects around 0.1% of the adult population. In
addition, pSS is second in rheumatic diseases, which is char-
acterized by immune infiltration in exocrine glands that
leads to functional impairment of the salivary and lacrimal
glands [1,2]. Saliva has many notable oral health functions
and salivary fluid is physiologically important for speech
modulation, efficient mastication, maintaining the oral
microbiota (increased oral bacterial and fungal infections),
and lubrication of the soft and hard tissues [3–5]. The oral
and salivary manifestations observed in pSS include dry
mouth, difficulty in chewing and swallowing food, and oral
burning symptoms [5–7]. Importantly, clinical manifesta-
tions from primary pSS patients and animal models of SS
point to the loss of salivary gland function that results from
abnormal autoimmune response; however, the mechanism
that initiates loss of salivary gland secretion is not well
understood [8,9]. Extra glandular manifestations are also
common for these patients, who show an enhanced lympho-
proliferation, with a greater risk of forming malignant
lymphoma. Histologically, pSS is characterized by extensive
lymphocytic infiltration that is observed in the salivary and
lacrimal gland tissues [8–12] and secretion of proteases,
such as serine proteases, could induce the loss of salivary
glands. Importantly, salivary gland cells have a measure that
can protect them against the proteases secreted by immune
cells; however, if these protective mechanisms are lost, they
may induce cell death [9,13,14].
Serpins are the largest and most broadly distributed
superfamily of protease inhibitors. These inhibitors are char-
acterized by the presence of three critical amino acids: histi-
dine, aspartate and serine, which is present in the catalytic
site [15–18]. Proteases secreted from lymphocytes play a
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major role in tissue degeneration, thus tissues such as saliv-
ary glands have developed a protective mechanism that
includes the presence of inhibitors that inhibits protease
activity thereby prevent cell death. One such protease
inhibitor is alpha-1 antiproteinase antitrypsin, which is a
circulating serine protease inhibitor (serpin) that inhibits
leukocyte elastase. One of these proteins, alpha-1 antiprotei-
nase antitrypsin is a major proteinase inhibitor, which is
produced in the gastrointestinal tract, liver, pancreas, gall
bladder and inflammatory cells [19]. Importantly, alpha-1
antiproteinase antitrypsin protein has been described previ-
ously in normal salivary gland cells and pleomorphic aden-
oma [20], but its function, especially in disease conditions,
is not clear. Also, alpha-1 antiproteinase antitrypsin has also
been claimed to have diverse cytoprotective and anti-inflam-
matory effects, suggesting that alpha-1 antiproteinase anti-
trypsin evoke a “pro-survival” response [17–20]. Alpha-1
antiproteinase antitrypsin is one of the main protease inhib-
itors in human serum and is important to control the
inflammatory response by inhibiting the excess elastase that
is produced from innate immune cells. Although the role of
alpha-1 antiproteinase antitrypsin in immune modulation is
been previously identified; its potential function in salivary
gland dysfunction, especially pSS is not yet established.
Importantly, alpha-1 antiproteinase antitrypsin therapy has
been shown to prevent or reverse autoimmune diseases, and
these effects were accompanied by changes in cytokine and
transcriptional profiles and T cell subsets [21–26], suggest-
ing that manipulations that can restore alpha-1 antiprotei-
nase antitrypsin expression, could be beneficial for
autoimmune diseases such as pSS.
Although the aetiology of pSS remains obscure, it has
been suggested that overactivation of the immune response
upon the interaction of environmental and/or genetic factors
may contribute towards the pathogenesis of pSS [1–7,27,28].
A significant association between pSS development and a
positive family history for autoimmune diseases has been
documented, indicating the importance of a genetic predis-
position [29,30]. Consistent with this, HLA DQB10201
-DRB10301 -DQA10501 haplotypes have been identified
that exhibit the strongest risk factors to produce an anti-
SSA/Ro, anti-SSB/La response. These responses are the hall-
marks of the pSS disease [30]. In addition, polymorphisms
in certain genes, such as STAT4, IL-12A, TNIP1, IRF5, BLK
and CXCR5 have been shown in pSS [30]. However, most
of these genetic mutations are far from DNA-coding regions
and they are suspected to alter disease-susceptibility genes
by altering their expression indirectly via an action on the
epigenetic machinery [31,32]. Epigenetics is defined as
changes in gene expression, that are inheritable and that do
not entail changes in the DNA sequence. Epigenetic mecha-
nisms are important to control the pattern of gene expres-
sion in response to biological or environmental changes.
Therefore, epigenetic dysregulations have been linked with
autoimmune diseases including pSS [33,34]. The precise
mechanism and the consequence of the epigenetic changes
are not known.
In this study, we have assessed the expression of alpha-1
antiproteinase antitrypsin in the salivary gland to see if it
corelates with pSS. We report here that alpha-1 antiprotei-
nase antitrypsin expression is important for Sjogren’s disease
onset/propagation using both pSS patients and mouse mod-
els that mimic Sjogren’s like disease. Importantly, we have
identified that certain epigenetic regulations could modulate
the expression of alpha-1 antiproteinase antitrypsin. pSS
patients displayed a severe reduction in stimulated saliva
secretion and alpha-1 antiproteinase antitrypsin expression
was substantially attenuated. Furthermore, mouse models that
mimic SS also showed a decrease in alpha-1 antiproteinase
antitrypsin expression that precedes acinar cell death.
Importantly, increased epigenetic changes including an
increase in expression of certain microRNA as well as DNA
methylation in the serpin gene was observed in human pSS
patients. Together, our findings suggest that regulation of
gene expression probably via epigenetic modulations are key
regulators for alpha-1 antiproteinase antitrypsin expression
that could be critical for salivary gland function and survival.
Materials and methods
Human samples and their analysis
Individuals, referred to the Sjogren Expertise Centre of the
University Medical Centre Groningen (UMCG) for evalu-
ation of pSS were screened for eligibility. Exclusion criteria
were age <18 years, an incomplete diagnostic workup (not
all parameters evaluated), diagnosis of another systemic
autoimmune disease, hepatitis C positivity, and renal
impairment. Patients that fulfilled the 2016 ACR-EULAR
criteria i.e. fulfil four out of six classification criteria for pSS
were classified as pSS patients and the remaining patients
that do not show at least four classification were identified
as non-SS (nonSS-SICCA) and were used as controls [35].
Serum samples of pSS patients were used for the character-
ization of Ro/La autoantibodies. Parotid gland biopsies from
all patients were obtained as part of a complete diagnostic
work-up, which was used for further studies as indicated
below. A total of 12 confirmed pSS and 11 non-SS-Sicca
were used for initial characterization followed by an add-
itional cohort of 10 pSS and 6 age-matched control. The
focus score was calculated by quantifying the total number
of foci in the specimen, which is divided by the glandular
surface area, and multiplied by 4, to give the number of foci
per 4mm2. Informed consent was obtained from all patients
according to the Declaration of Helsinki and the study was
approved by the Medical Research Ethics Committee of
the UMCG.
Animals and reagents
All animal experiments were performed according to the
ARRIVE guidelines. IL14a transgenic mice and related con-
trol B6 mice were housed in a 12-h light/dark cycle with ad
libitum accesses to lab chow and water in germ free condi-
tions as described previously by us [36]. Animals were
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maintained in accordance with the guidelines established by
the Institutional Animal Care and Use Committee. All ani-
mals used were females between 6 and 12months of age
and are regularly tested for common pathogens. Number of
mice used for each experiment is included in the figure
legends. Unless mentioned otherwise, all reagents used in
the study were of molecular biology grade obtained from
Sigma Chemicals (St. Louis. MO).
2D gel electrophoresis and mass spectrometry
Human parotid tissue samples from six control (non-SS-
SICCA) and six pSS samples were ground using mortar and
pestle and homogenized in lysis buffer using a glass hom-
ogenizer as previously described by us [37]. Protein samples
were quantified and labelled using spectrally distinct charge
and mass-matched fluorescent dyes cyanine-3, (Cy3 – green
for non-SS-SICCA), cyanine-5 (Cy5 – red for pSS) mixed
and resolved simultaneously on a 2D gel. Proteins labelled
with different CyDye was visualized and quantified using
DeCyder differential analysis software [38]. The identity of
individual spots was determined by using Liquid
Chromatography that was linked with tandem mass spec-
trometry. Briefly, individual spots that were only present in
controls and absent in pSS were excised from the 2D gel,
treated with trypsin for digestion, and the pool of peptides
were separated using a Nano HPLC that are processed by a
tandem mass spectrometer. The peptide data from individ-
ual spots were aligned using the MASCOT database search.
MicroRNA and RT-PCR
Human parotid tissues from individual (3 control and 3 pSS)
biopsies (10ng) as described above were extracted and pulv-
erised using a mortar and pestle over dry ice. Total RNA,
from the powdered tissues, were extracted using Trizol
reagent, RIN calculations were performed to estimate the
quality of the RNA, reverse transcribed, and PCR amplified
using standard procedures as described earlier [39]. miRNA
was evaluated using a customised microarrays that had over
1600 known human miRNAs and control and pSS RNA sam-
ples were labelled with two different fluorophores and hybri-
dised to identify the expression of individual miRNAs.
Quantification of the flourophore of the hybridised
microRNA was used to identify relative expression of individ-
ual microRNAs. Target validation was performed using
Target scan and appropriate controls were used to naormalize
the data. A 5-ml aliquot of the amplified product was resolved
on a 1.5% agarose gel and the EtBr-stained bands were
visualised using the Bio-Rad imager. Quantitative PCR was
carried out using SYBR Green SensiMix (Quantace) accord-
ing to the manufacturer’s instructions on a Light Cycler 480
(Roche). Pre-miR-132 primers used were CCGTGGCTTTCG
ATTG and GGCGACCATGGCTGTAGAC. Standard curves
were constructed by plotting the threshold cycle (Ct) values
against logarithm10 of the copy number and fitting by linear
least square regression.
Immunohistochemistry and imaging
Human salivary glands (both parotid and minor glands
from 6 control SICCA and 6 pSS) and parotid glands from
mice were fixed in 4% paraformaldehyde in 0.1M phosphate
buffer (pH 7.2) containing 5% sucrose as previously
described [37,39,40]. Tissues were placed overnight in the
same buffer as before containing 20% sucrose. Tissues were
then embedded in Tissue-Tek OCT compound, frozen for
6 h and 10–12 mm thick cryosections were obtained.
Haematoxylin and eosin (H&E) staining was performed on
the sections using the standard procedure (Sigma, St. Louis,
MO). Light images were obtained at 40 magnifications.
For fluorescent confocal imaging, salivary gland sections
from respective animals or from human biopsies were per-
meabilized at room temp with 0.1% TritonX-100 in PBS
(pH 7.4), blocked (using 10% donkey serum and 5% BSA in
PBS) and probed overnight with the respective primary anti-
bodies in a hydrated chamber maintained at 4 C. Following
incubation with the primary antibodies, the slides were
washed and incubated with fluorophore-conjugated respect-
ive secondary antibodies for 1 h at room temperature.
Thereafter the slides were washed, and coverslip mounted
using vectashield hardest mounting media with DAPI
(Vector Laboratories, CA). Tunnel staining was performed
using abcam tunnel assay kits. Images were acquired at 63
magnifications using a confocal laser-scanning LSM 510
Meta microscope (Carl Zeiss, Thornwood, NY).
Morphological details and fluorescence were analysed using
Image-J software (NIH). The antibodies used were the fol-
lowing monoclonal or polyclonal antibodies: anti-alpha-1
Antitrypsin Monoclonal Antibody (Invitrogen Cat#
TMF1#4B5); Dilution in 1:100), anti-elastase (abcam; Cat#
ab68672; Dilution used were 1:100), anti-F4/80 (abcam, MA;
Cat# A3-1; Dilution used was 1:100), and anti-b-Actin (Cell
Signalling, MA; Cat# 4970, at 1:200 dilution).
DNA methylation
Genomic DNA from non-SS-SICCA (control) and pSS sam-
ples were extracted using the Qiagen-DNeasy Blood &Tissue
Kit according to the supplier’s instructions (Qiagen). This
included a proteinase K digestion at 55 C overnight. DNA
was quantitated with the Nanodrop ND-1000 UV–Vis
Spectrophotometer (Nanodrop Technologies, Wilmington,
DE, USA). Site-specific CpG methylation was analysed using
InfiniumVR Human Methylation 450K bead-array-based
technique. Genomic DNA (1 mg) was treated with sodium
bisulphite using the Zymo EZ DNA Methylation KitTM
(Zymo Research, Orange, USA) according to the manufac-
turer’s procedure, with the alternative incubation conditions
recommended when using the Illumina InfiniumVR
Methylation Assay [41]. The methylation assay was per-
formed from 4 ml converted gDNA at 50 ng/ml according to
the InfiniumVR Methylation Assay Manual protocol. The
quality of bead array data was checked with the
GenomeStudioTM Methylation Module software.
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Statistics
Data analysis was performed using Microsoft Excel or
Origin 7.0 (Origin Lab). Statistical comparisons were made
using one-way ANOVA. Experimental values are expressed
as means ± SD or SEM. Differences in the mean values were
significant at p< .05.
Results
Patient characteristics
Control (non-SS Sicca) or pSS patients that were referred to
the clinic were evaluated further based on the pSS criteria
and samples from individuals that fulfil the pSS classifica-
Figure 1. Characterizationz of pSS patients. Patients (12 pSS and 11 control non-SS Sicca) were evaluated based on the ACR-EULAR criteria and saliva flow in con-
trol non-SS Sicca and pSS patients was evaluated. (A) indicates unstimulated, whereas stimulated saliva in non-SS-SICCA and pSS individuals is shown in (B). Error
bars represent means ± SD,  indicates p< .05, respectively. C shows the quantification of the IgM RA factor between the non-SS-Sicca and pSS samples.  indicates
a significant difference (p< .005). Description of non-SS-SICCA and pSS individuals along with histopathology and other parameters (including focus score, autoan-
tibodies and histopathology) that were measured are provided in (D).
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tion were used for this study. To identify changes in the
expression of salivary gland proteins we used parotid gland
tissues from age-matched non-SS-SICCA (as controls) and
pSS patients. As shown in Figure 1, a significant decrease in
basal unstimulated saliva was observed in pSS samples when
compared with age-matched non-SS-SICCA (Figure 1(A),
80% decrease). In addition, stimulated saliva was also sig-
nificantly decreased in pSS patients (Figure 1(B)). We next
evaluated the IgM rheumatoid factor which was significantly
increased (more than 10-fold) in pSS patients (Figure 1(C)).
In addition, both anti-Ro and La autoantibodies were pre-
sent in pSS samples, but absent in age-matched non-SS-
SICCA samples, except in one patient where La antibody
was not observed but had all other characteristics necessary
to confirm pSS (Figure 1(D)). Tissues samples were sec-
tioned and stained for H&E, which showed infiltration of
immune cells in SS samples when compared with SICCA
samples (Figure 1(D), where positive indicates infiltration
along with the focus score). Importantly, pSS samples also
showed lymphoepithelial lesions (LEL) with a Chisholm
score of more than 3 was termed positive for pSS samples.
In addition, a shift to IgG anti-Ro/SSA was also observed in
the biopsy samples of pSS when compared with non-SS-
SICCA samples (Figure 1(D)). Together, these results con-
firm that the patients had pSS and were thus used for fur-
ther evaluation.
Loss of alpha-1 antiproteinase antitrypsin in
pSS samples
The use of 2D-DIGE in quantitative proteomics permits the
inclusion of multiple sample groups within the experimental
design. Thus, we took advantage of this technology to inves-
tigate and compare the expression of various proteins in
non-SS-SICCA and pSS samples. Total proteins were iso-
lated from parotid glands of non-SS-SICCA and pSS and
labelled with different fluorophores. This allowed us to com-
pare both non-SS-SICCA and pSS conditions, as well as to
compare individual samples, permitting the identification of
proteins that showed a difference in abundance in pSS as
compared to non-SS-SICCA. To minimize system and
inherent biological variation, samples were labelled and mul-
tiplexed following these guidelines: (a) replicates from each
group were alternatively labelled with Cy3 or Cy5, known as
dye swapping; and, (b) two samples from the same experi-
mental group were included in the same gel along with an
internal standard used for quantification. A representative
dye overlay gel image is shown in Figure 2(A) and as indi-
cated two visible spots (labelled as 1-2 were observed in
non-SS-SICCA samples that were either absent or decreased
in pSS samples (Figure 2(A)). The DeCyder DIA module
was used to detect and quantify the spots that exhibited
statistically significant expression changes of ±1.3 fold
(ANOVA, p< .05) and confirmed that the two spots were
decreased in pSS samples (Figure 2(B)). Matching between
the different gels was done through internal standard gel
images using the BVA module. Expression changes were cal-
culated for each protein spot between the two groups and
derived from the log standardized protein abundance
changes that were directly quantified within each DIGE gel,
relative to the internal standard for the protein spot, which
showed a 3-fold decrease in the expression of spot 1- and 2-
fold decrease in spot 2 (Figure 2(C)).
To establish the identity of these proteins, both spots
(from two individual gels) were excised from the gels and
successfully identified using LC-MS/MS. The protein spots
correspond to alpha-1 antiproteinase antitrypsin which was
identified using 15 or unique peptides with a confidence of
99% at the protein level and 100% at the peptide level
(Table 1). The MS/MS peptide sequence, precursor ion (m/
z) and charge number are shown in the table and both the
spots contained only a single protein. Furthermore, the
experimental isoelectric focussing and molecular mass values
agree with the corresponding theoretical values for all the
spots identified, which increased our confidence. Overall,
the data presented above suggest that alpha-1 antiproteinase
antitrypsin expression is significantly decreased in pSS sam-
ples and could contribute towards the pathogenesis. To sup-
port the proteomic results, we next determined the
expression of alpha-1 antiproteinase antitrypsin using con-
focal microscopy. As indicated in Figure 3 alpha-1 antipro-
teinase antitrypsin was expressed in the salivary gland cells
obtained from non-SS-SICCA patient’s patients but was
decreased in pSS samples (Figure 3(A)). In contrast, no
change in the actin levels was observed between the two
samples (non-SS-SICCA and pSS) (Figure 3(A)). The DIC
and the DAPI image confirmed that the sections had both
acinar and ductal cells and alpha-1 antiproteinase antitryp-
sin was expressed in the cytoplasm of the salivary gland
cells. Overall the confocal studies confirm our proteomics
data thereby showing that indeed salivary gland cells express
alpha-1 antiproteinase antitrypsin, which was decreased in
pSS samples.
Leucocyte infiltration and loss of alpha-1 antiproteinase
in mouse models SS precede salivary gland degeneration. To
establish that indeed loss of alpha-1 antiproteinase antitryp-
sin, which is observed in human samples is also observed in
animal salivary gland, we used the IL14a Tg mouse model
that shows characteristics like pSS [36]. Sj€ogren’s syndrome
patients expressed high level of IL14a in their peripheral
blood. Similarly, IL14a overexpressing transgenic mice
develop hypergammaglobulinemia, autoantibodies, infiltra-
tion of the parotid glands with lymphocytes, mild immune-
complex mediated renal disease and large B cell lymphoma,
and thus, are suggested as mouse models for SS.
Importantly, 12months old control mouse showed expres-
sion of alpha-1 antiproteinase antitrypsin in the parotid
gland tissues, whereas 12months old IL14a Tg mice showed
decreased alpha-1 antiproteinase antitrypsin expression
(Figure 3(B)). Again, no change in the actin levels was
observed between salivary gland samples obtained from con-
trol and IL14a mouse models (Figure 3(B)). We next eval-
uated, if the expression of alpha-1 antiproteinase antitrypsin
is decreased in earlier months and our results indicate that
3months old IL14a Tg mice did not show any difference in
alpha-1-antitrypsin expression (data not shown).
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Importantly, this decrease in alpha-1-antitrypsin expression
coincides with the presence of immune infiltrates which
were significantly increased in 12-month-old IL14a Tg
mouse models of pSS (Figure 3(C)). Furthermore, tunnel
staining that indicates apoptosis in salivary parotid glands
was also increased in IL14a mouse models of SS when com-
pared with age-matched controls (Figure 3(C)). Together
these results suggest that loss of alpha-1 antiproteinase anti-
trypsin expression in the salivary gland epithelial cells could
subject salivary tissues vulnerable towards enhanced prote-
ase activity that could lead to the loss of salivary tissues.
The data presented above suggest that in both pSS sam-
ples as well as in SS mouse models there is a decrease in
alpha-1 antiproteinase antitrypsin expression, which could
lead to an increase in leucocyte elastase. To confirm this, we
again used the IL14a Tg mouse model, which showed an
age-dependent increase in elastase staining. Importantly,
3months old mice failed to show any expression of elastase
and no difference in the staining between control and IL14a
Tg mice was observed (Figure 4(A)). In contrast, 6 and 12-
month-old IL14a Tg mice showed a gradual increase in
elastase expression, which was absent in age-matched con-
trol parotid salivary gland cells. Importantly, a significant
loss of acinar cells was observed in the region where elastase
expression was present (Figure 4(A)). Like the mouse data,
human samples also showed an increase in elastase activity
(Figure 4(B)), which further supports that loss of alpha-1
antiproteinase expression could increase elastase activity.
Figure 2. Differential expression of proteins in control and pSS samples. (A) 2D separation of individual proteins based on PI and molecular weight in non-SS
SICCA and pSS samples (data shown is representation of six control non-Sicca and six pSS samples). Individual proteins were labelled using two different dyes
(green was used to label non-SS-SICCA; whereas, red was used to label pSS) and differential expression of individual proteins was evaluated based on the colour
difference on the 2 D-gel. Individual spots were quantification using DeCyder analysis (B) and decrease in the fold change of spot 1 and 2 were determined in C.
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Together, these results suggest that loss alpha-1 antiprotei-
nase expression in pSS leads to increased leukocyte elastase
activity that promotes the loss of salivary gland cells.
miR-132 may be responsible for the loss of alpha-1
antiproteinase antitrypsin in SS
The results shown above provide substantial evidence that
alpha-1 antiproteinase antitrypsin expression is decreased in
pSS glandular tissue as well as in a mouse model of SS that
could make them susceptible to various proteases that could
subsequently lead to loss of salivary tissues. However, yet,
there has been no report demonstrating why alpha-1 anti-
proteinase antitrypsin expression is decreased in pSS. Gene
expression is controlled by several mechanisms that include
epigenetic modifications as well as the up-regulation of cer-
tain microRNAs. Thus, we next evaluated if microRNAs
that can inhibit expression of the gene that encodes for
alpha-1 antiproteinase antitrypsin are altered in pSS.
Importantly, we evaluated all the microRNAs that bind to
the 30 UTR region of the serpina1 gene (codes for alpha-1
antiproteinase antitrypsin) and thus could target alpha-1
antiproteinase, antitrypsin expression (Figure 5(A)).
However, besides miR-132 that showed a 4 fold increased
in the parotid samples obtained from pSS patients; whereas,
all other microRNAs (miR-181, 140, 143, 24, 7, 190, 214,
330) that could target serpina1 expression did not show any
significant changes in pSS (Figure 5(B)). To further confirm
that indeed miR-132 expression is increased quantitative
PCR was performed, which confirmed a significant increase
in pSS samples when compared with non-SS-SICCA con-
trols (Figure 5(C)). miR-330 was used as a control and did
not show any difference between the two samples (data not
shown). In addition, the seed sequence needed for target
binding of miR-132 was conserved and the mirSVR (that
uses the algorithm score), as well as the PhastCons score
(that shows the conservation score), were substantially
higher, suggesting that mir132 binds to serpin gene. It is
thus conceivable that overexpression of miR-132 may be
responsible for inhibiting alpha-1 antiproteinase antitrypsin
expression in pSS.
An increase in DNA methylation of the serpin gene is
observed in SS samples
DNA methylation is also an important epigenetic control
mechanism that regulates the pattern of gene expression in
response to biological or environmental changes. Thus, we
also probed if epigenetic modifications mainly DNA methy-
lation patterns are altered as that could be another critical
step involved in the regulation of alpha-1-antitrypsin expres-
sion. Using the gene browser, we looked at the gene region
for all serpin genes. Importantly, all the serpin genes were
clustered at a DNA location and showed the CpG islands
that were present in both the promoter region as well as in
the non-coding region of the gene (Figure 6(A,B)).
Table 1. Peptide information of the spots that were differentially expressed between control and pSS samples are shown in A.
A
Spot # Protein identification Accession no. Protein MW Protein PI Peptide count
Spot 1 Alpha-1-antitrypsin gij1942953 44264.8 5.43 16
Spot2 Alpha-1 antiproteinase, antitrypsin-1 gij50363219 46707 5.37 16
Spot3 Uncleaved alpha-1-antitrypsin gij2392173 41969.9 5.56 13
Spot4 Alpha-1 antiproteinase, antitrypsin-1 gij54695780 46679 5.37 15
B
Peptide Information
Calc. Mass Observation mass ± da ± ppm Start End Sequence Ion score C.I. % Modification
1076.6173 1076.5676 0.0497 46 259 267 LSSWVLLMK
1078.5276 1078.4888 0.0388 36 299 306 FLENEDRR
1090.568 1090.5288 0.0392 36 218 225 WERPFEVK
1090.568 1090.5288 0.0392 36 218 225 WERPFEVK 15 0
1110.6041 1110.5576 0.0465 42 324 LSITGTYDLK
1247.6024 1247.5497 0.0527 42 248 257 LGMFNIQHCK Carbamidomethyl (C)[9]
1263.5973 1263.5562 0.0411 33 248 257 LGMFNIQHCK Carbamidomethyl (C)[9],
Oxidation (M)[3]
1275.6844 1275.6346 0.0498 39 216 225 GKWERPFEVK
1275.6844 1275.6346 0.0498 39 216 225 GKWERPFEVK 22 0
1641.8635 1641.7922 0.0713 43 50 63 ITPNLAEFAFSLYR 68 99.983
1641.8635 1641.7922 0.0713 43 50 63 ITPNLAEFAFSLYR
1779.7682 1779.6874 0.0808 45 35 49 TDTSHHDQDHPTFNK
1803.96 1803.8821 0.0779 43 284 298 LQHLENELTHDIITK
1833.9229 1833.8414 0.0815 44 335 352 VFSNGADLSGVTEEAPLK 114 100
1833.9229 1833.8414 0.0815 44 335 352 VFSNGADLSGVTEEAPLK
1855.9775 1855.8904 0.0871 47 390 404 FNKPFVFLMIEQNTK 79 99.999
1855.9775 1855.8904 0.0871 47 390 404 FNKPFVFLMIEQNTK
1863.8243 1863.7407 0.0836 45 226 241 DTEEEDFHVDQATTVK
1871.9724 1871.8879 0.0845 45 390 404 FNKPFVFLMIEQNTK Oxidation (M)[9]
2057.9451 2057.855 0.0901 44 161 178 LYHSEAFTVNFGDTEEAK 134 100
2057.9451 2057.855 0.0901 44 161 178 LYHSEAFTVNFGDTEEAK
The individual mass of the peptides was analyzed using the MASCOT protein data bank and more than 30% coverage was obtained for each spot is shown
in B.
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Moreover, a comparison of the DNA methylation sites
(evaluation of all predicated DNA methylation sites) in
human pSS and non-SS SICCA parotid samples identified
three main regions where the serpina1 gene has increased
levels of methylation in pSS samples compared to non-SS
SICCA, whereas other regions had no change in DNA
methylation (Figure 6(C)). Hypermethylation in these DNA
segments could also lead to a decrease in the expression of
alpha-1-antitrypsin expression. We next evaluated if other
serpin genes are also altered in their DNA methylation pat-
tern. In contrast, serpin B5 did not show a significant
increase in the DNA methylation in pSS samples when
Figure 3. Alpha 1 antitrypsin expression is decreased in pSS samples as well as in the mouse model for Sjogren’s syndrome. 10uM sections were obtained from
parotid glands and the expression of individual proteins was assessed. (A) Representative confocal images showing staining with alpha 1 antitrypsin and actin anti-
bodies in control and pSS samples data obtained was from four control and six pSS minor or parotid salivary glands. Similarly, parotid glands of SS mouse model
(IL14a) were also sectioned and expression (data shown is a representation from three control and three IL14aTg mice) of alpha 1 antitrypsin was evaluated and
shown in (B). (C) Shows H&E staining in salivary gland from control and IL14a mice (images are representation of three individual samples performed in duplicate).
Marker for apoptosis (Tunnel staining) and immune cells (CD11b and F4/80) was also used to evaluate cell death and immune infiltration in control and IL14a
mice. (D) Total saliva was estimated for 20min in control (8 female mice) and 10 age-matched female IL14aTg mice. Error bars represent means ± SD and  indi-
cates p< .05.
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compared with non-SS-SICCA samples (Figure 6(D)), sug-
gesting that hypermethylation was specific for serpina1 and
more research is needed to fully evaluate the expression of
these specific isoforms. In contrast, decreased methylation
was observed in the serpin A7 gene region in pSS samples
(Figure 6(E)), which could affect the expression of serpin
A7. Together these results suggest that epigenetic modifica-
tion such as DNA methylation could also alter the expres-
sion of these key genes that are important for the protection
of salivary gland cells.
Discussion
Regulated secretion of salivary fluid, which is mediated
through the salivary glands, is a critical determinant of oral
health. Salivary fluid secretion is decreased in various patho-
logical conditions including pSS. However, the molecular
mechanisms that underlie the loss of receptor-induced fluid
secretion in pSS remain poorly defined. In this study, we
showed that alpha1-antitrypsin protein expression was
decreased in pSS samples when compared with age-matched
non-SS SICCA controls. Our results not only confirm the
expression of alpha1-antitrypsin in salivary gland cells but
also suggest a potential role during the development of pSS.
Alpha-1 antiproteinase antitrypsin has been shown as an
acute-phase protein [42], thus, it seems logical to assume
that increase in the expression of alpha-1 antiproteinase
antitrypsin could be important to combat immune activa-
tion and to protect against these proteases. Alpha-1 antipro-
teinase antitrypsin is widely distributed in body fluids, and
its concentration is especially increased in acute inflamma-
tory responses. Importantly, in intestinal epithelia, it is sug-
gested that alpha-1 antiproteinase antitrypsin may be an
important self-protective mechanism against various pro-
teases such as the pancreatic proteolytic enzymes as well as
and collagenase released from leucocytes [43]. As salivary
and pancreatic glands secrete similar proteases and have
similar structure involving acini and the ductal system, it
could be suggested that alpha 1 antiproteinase antitrypsin
could be part of the self-defence mechanism in salivary
glands as well. This is consistent with the data presented
here, which showed that non-SS-SICCA salivary tissues have
adequate expression of alpha-1 antiproteinase antitrypsin,
which could support normal function. The self-controlling
mechanism is important for maintaining the integrity of tis-
sues in the oral cavity, which is related to the secretion of
proteins that can counter the elastase and collagenase
Figure 4. Increased elastase expression in pSS samples as well as in IL14a mice. 10uM sections were obtained from submandibular glands and expression of leuco-
cyte elastase was assessed in control and age-matched IL14a mice (A). Representative confocal images showing staining with elastase antibodies in control and
pSS samples are shown in (B). Images shown are representation of three individual samples (three controls and three pSS or IL14-Tc live) peq/oqled
im dtpkivase.
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produced from immune cells. Lymphocytic infiltration of
the salivary and lachrymal glands is the classical hallmark of
pSS [3] that also secretes proteases, such as serine proteases
and could contribute to loss of salivary gland tissue. Our
results show that a decrease in alpha-1 antiproteinase anti-
trypsin in pSS samples and an increase in cell death was
also observed in mouse samples that are models for SS;
however, if this is a causal relationship, it needs to be fur-
ther explored. Importantly, the presence of an alpha-1 anti-
proteinase antitrypsin in salivary glands may indicate that
one purpose of this protein could be to function as a
defense mechanism and inhibit the degradation of the saliv-
ary gland cells. This is consistent with the data presented
here as both increases in tunnel staining and a decrease in
alpha-1 antiproteinase antitrypsin staining was observed in
the animal models of pSS.
We next identified the factors that could explain as why
the expression of alpha-1 antiproteinase antitrypsin was
decreased in pSS. Epigenetic modifications have been shown
to alter gene expression as well as contribute to pSS
[34,44,45], thus, we focussed our attention to see if epigen-
etic modifications are altered in pSS patients. DNA methyla-
tion has been long proposed that is responsible for the
stable maintenance of gene expression patterns [41,46].
Specifically, DNA methylation establishes a silent chromatin
state by collaborating with proteins that modify
nucleosomes [43]. Importantly, our results showed that
DNA methylation was altered in serpinina1 gene encoding
for alpha-1 antiproteinase antitrypsin. DNA methylation is a
post-replication modification that is predominantly found in
cytosines of the dinucleotide sequence CpG. The extent of
DNA methylation changes in an orchestrated way and alter-
ations in DNA methylation has been shown in various dis-
ease conditions. In cancer cells, methylation of CpG islands
is known to contribute to gene silencing, suggesting that a
similar mechanism could also be present in pSS, which
needs to be further identified. Here we show that increased
methylation in the promoter region of the serpinina1 gene
was observed, which could inhibit the expression of alpha-1
antiproteinase antitrypsin protein. This was also specific as
no significant decrease in other serpin genes was observed.
Similarly, other epigenetic modifications such as histone
modifications could also alter gene expression, and future
research is needed to show if histone modifications are also
altered in pSS.
Growing evidence indicates that microRNAs are involved
in a variety of basic biological processes, including regulat-
ing gene expression and in pSS [47]. microRNAs bind to a
specific region of mRNA (mainly 30 untranslated region)
and as only a few bases of the seed sequence are needed to
bind to the target mRNA, they may regulate multiple tar-
gets and can be important in every biological pathway.
Figure 5. Expression of microRNAs that affect the serpin 1 gene. (A) illustrations showing various microRNA binding sites at the 30 untranslated region of the ser-
pina1 gene. Alterations in the expression of various microRNAs in the parotid tissues of pSS patints as compared with control non SS Sicca are shown as fold
change in (B) Data presented are representation of three individual samples (three controls non SS Sicca and three pSS) performed in duplicate. (C) Shows relative
quantification of miR132 in non-SS-Sicca and pSS samples. Error bars represent means ± SD and  indicates p< .05.
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Here, we show that, compared with normal salivary tissue,
microRNA 132 that binds to the serpina1 gene was
increased (4-fold) in pSS sample versus non-SS-SICCA tis-
sues. This is in accordance with previous studies which
showed that the expression of alpha1 antitrypsin is
dependent on the expression of mir-132 [48]. Interestingly,
the binding of mir-132 to the serpin mRNA could trigger
translation repression or degradation of the serpin RNA,
which could decrease its expression as observed in pSS
samples. Of prime significance, our study identifies a pos-
sible epigenetic mechanism that increases proteases such as
elastases that could contribute towards the loss of salivary
gland tissues and explain why salivary gland function is
decreased in pSS. Our data suggest that loss of serpin gene
expression decreases alpha-1 antiproteinase antitrypsin
protein which is unable to protect salivary gland cells
against protease secreted by salivary and infiltrating
immune cells. This attribute is mechanistically connected
to the selective regulation of epigenetic mechanisms which
results in the impaired expression of alpha-1 antiproteinase
antitrypsin. Although the loss of an alpha-1 antiproteinase
antitrypsin influences salivary gland cells, our data does
Figure 6. DNA methylations in the serpin gene. (A) Gene browser image showing the locus that clusters various serpin genes in humans. Model showing various
DNA methylation sites as well as the exons/intron regions of serpina1 (B). Evaluation of all the DNA methylation sites on the serpina1 gene is shown as a bar graph
in (C). Data presented are representation of samples from four controls non SS Sicca and four pSS samples performed in duplicate. Error bars represent means ± SD
and  indicates p< .05. Evaluation of DNA methylation sites on the serpin B5 (D) and serpin A7 (E) gene are shown as bar graphs. Error bars represent means ± SD
and  indicates p< .05.
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not show if the expression of alpha-1 antiproteinase anti-
trypsin is decreased in other tissues. It is important to note
that, alpha-1 antiproteinase antitrypsin is an acute-phase
protein and more research is needed to establish if the
expression of alpha-1 antiproteinase antitrypsin in other
tissues is also epigenetically regulated. A distinct aspect of
our study is that we show for the first time that loss of
alpha-1 antiproteinase antitrypsin could contribute towards
pSS. Thus, either reconstitution of alpha-1 antiproteinase
antitrypsin expression or inhibition of elastase and other
proteases could be a possible new therapy option to protect
salivary gland dysfunction in pSS.
Acknowledgments
The authors acknowledge The Edward C. Carlson Imaging and Image
Analysis core facility.
Disclosure statement
No potential conflict of interest was reported by the author(s).
Author contributions
Conceptualization, methodology, and analysis, B.B.S. J.O, A.V., J.A and
B.B.M. Investigation, J.O, F..Q. Z., P.C and Writing–Review and
Editing, B.B.S. J.O, A.V., F.G.M.K. J.A, and B.B.M.
Funding
This work was supported by the National Institutes of Health Grants
DE017102, DE022765 (to B.B.S.). National Institute of Dental and
Craniofacial Research.
ORCID
Brij B. Singh http://orcid.org/0000-0003-0535-5997
References
[1] Fox PC. Autoimmune diseases and Sjogren’s syndrome: an
autoimmune exocrinopathy. Ann N Y Acad Sci. 2007;1098:
5–21.
[2] Meijer JM, Meiners PM, Huddleston Slater JJ, et al. Health-
related quality of life, employment, and disability in patients
with Sjogren’s syndrome. Rheumatology. 2009;48(9):1077–1082.
[3] Mariette X, Criswell LA. Primary Sj€ogren’s syndrome. N Engl J
Med. 2018;378(10):931–939.
[4] Dawes C, Pedersen AM, Villa A, et al. The functions of human
saliva: a review sponsored by the World Workshop on Oral
Medicine VI Arch. Arch Oral Biol. 2015;60(6):863–874.
[5] Rischmueller M, Tieu J, Lester S. Primary Sj€ogren’s syndrome.
Best Pract Res Clin Rheumatol. 2016;30(1):189–220.
[6] Cartee DL, Maker S, Dalonges D, et al. Sj€ogren’s syndrome:
oral manifestations and treatment, a dental perspective. J Dent
Hyg. 2015;89:365–371.
[7] Baum BJ, Alevizos I, Chiorini JA, Cotrim AP, et al. Advances
in salivary gland gene therapy - oral and systemic implications.
Expert Opin Biol Ther. 2015;15(10):1443–1454.
[8] Leehan KM, Pezant NP, Rasmussen A, et al. Fatty infiltration
of the minor salivary glands is a selective feature of aging but
not Sj€ogren’s syndrome. Autoimmunity. 2017;50(8):451–457.
[9] Rodrigues RA, Soares R. Inflammation in Sj€ogren’s syndrome:
cause or consequence? Autoimmunity. 2017;50(3):141–150.
[10] Kassan SS, Moutsopoulos HM. Clinical manifestations and
early diagnosis of Sjogren syndrome. Arch Intern Med. 2004;
164(12):1275–1284.
[11] Mavragani CP, Moutsopoulos HM. Sj€ogren’s syndrome. Annu
Rev Pathol. 2014;9:273–285.
[12] Tzioufas AG, Voulgarelis M. Update on Sj€ogren’s syndrome
autoimmune epithelitis: from classification to increased neopla-
sias. Best Pract Res Clin Rheumatol. 2007;21(6):989–1010.
[13] Nakata H, Yamamoto M, Kumchantuek T, et al. Synthesis,
localization and possible function of serine (or cysteine) peptid-
ase inhibitor, clade B, member 6a (Serpinb6a) in mouse sub-
mandibular gland. Cell Tissue Res. 2017;369(3):513–526.
[14] Sukumaran P, Sun Y, Zangbede FQ, et al. TRPC1 expression
and function inhibit ER stress and cell death in salivary gland
cells. FASEB Bioadv. 2019;1(1):40–50.
[15] Davies MJ, Lomas DA. The molecular aetiology of the serpino-
pathies. Int J Biochem Cell Biol. 2008;40(6-7):1273–1286.
[16] Krem MM, Di Cera E. Conserved Ser residues, the shutter
region, and speciation in serpin evolution. J Biol Chem. 2003;
278(39):37810–37814.
[17] Hunt JM, Tuder R. Alpha 1 anti-trypsin: one protein, many
functions. Curr Mol Med. 2012;12(7):827–835.
[18] Janciauskiene SM, Nita IM, Stevens T. Alpha1-antitrypsin
exerts in vitro anti-inflammatory activity in human monocytes
by elevating cAMP. J Biol Chem. 2007;282(12):8573–8582.
[19] Gauldie J, Lamontagne L, Horsewood P, et al. Jenkins E
Immunohistochemical localization of alpha 1-antitrypsin in
normal mouse liver and pancreas. Am J Pathol. 1980;101(3):
723–735.
[20] Perez P, Adriaansen J, Goldsmith CM, et al. Transgenic a-1-
antitrypsin secreted into the bloodstream from salivary glands
is biologically active. Oral Dis. 2011;17(5):476–483.
[21] Churg A, Dai J, Zay K, et al. Wright Alpha-1-antitrypsin and a
broad spectrum metalloprotease inhibitor, RS113456, have simi-
lar acute anti-inflammatory effects. Lab Invest. 2001;81(8):
1119–1131.
[22] Nita IM, Serapinas D, Janciauskiene SM. Alpha1-antitrypsin
regulates CD14 expression and soluble CD14 levels in human
monocytes in vitro. Int J Biochem Cell Biol. 2007;39(6):
1165–1176.
[23] Goldstein S, Reddy P. Tolerance without toxicity? a1-antitryp-
sin as a novel alternative to immunosuppression. Expert Rev
Clin Immunol. 2012;8(5):397–399.
[24] Tawara I, Sun Y, Lewis EC, et al. Alpha-1-antitrypsin mono-
therapy reduces graft-versus-host disease after experimental
allogeneic bone marrow transplantation Proc. Proc Natl Acad
Sci USA. 2012;109(2):564–569.
[25] McLean C, Greene C, McElvaney NG. Gene target therapeutics
for liver disease in alpha-1 antiproteinase, antitrypsin defi-
ciency. Biol Targets Therapy. 2009;3:63–75.
[26] Daemen MA, Heemskerk VH, van’t Veer C, et al. Functional
protection by acute phase proteins alpha(1)-acid glycoprotein
and alpha(1)-antitrypsin against ischemia/reperfusion injury by
preventing apoptosis and inflammation. Circulation. 2000;
102(12):1420–1426.
[27] Ice JA, Li H, Adrianto I, et al. Genetics of Sj€ogren’s syndrome
in the genome-wide association era. J Autoimmun. 2012;39(1-
2):57–63.
[28] Priori R, Medda EF, Conti EA, et al. Risk factors for Sj€ogren’s
syndrome: a case-control study. Clin Exp Rheumatol. 2007;25:
378–384.
[29] Cruz-Tapias P, Rojas-Villarraga A, Maier-Moore S, et al. HLA
and Sj€ogren’s syndrome susceptibility. A meta-analysis of
worldwide studies. Autoimmun Rev. 2012;11(4):281–287.
AUTOIMMUNITY 281
[30] Lessard CJ, et al. Variants at multiple loci implicated in both
innate and adaptive immune responses are associated with
Sj€ogren’s syndrome. Nat Genet. 2013;11:1284–1292.
[31] Dozmorov MG, Wren JD, Alarcon-Riquelme ME. Epigenomic
elements enriched in the promoters of autoimmunity suscepti-
bility genes. Epigenetics. 2014;9(2):276–285.
[32] Brooks WH, Le Dantec C, Pers JO, et al. Epigenetics and auto-
immunity. J Autoimmun. 2010;34(3):J207–219.
[33] Renaudineau Y. The revolution of epigenetics in the field of
autoimmunity. Clin Rev Allergy Immunol. 2010;39(1):1–2.
[34] Imgenberg-Kreuz J, Sandling JK, Nordmark G. Epigenetic alter-
ations in primary Sj€ogren’s syndrome - an overview. Clin
Immunol. 2018;196:12–20.
[35] van Nimwegen JF, van Ginkel MS, Arends S, et al. Validation
of the ACR-EULAR criteria for primary Sj€ogren’s syndrome in
a Dutch prospective diagnostic cohort. Rheumatology. 2018;
57(5):818–825.
[36] Shen L, Zhang C, Wang T, et al. Development of autoimmunity
in IL-14alpha-transgenic mice. J Immunol. 2006;177(8):
5676–5686.
[37] Pani B, Xibao L, Bollimuntha S, et al. Impairment of TRPC1-
STIM1 channel assembly and AQP5 translocation compromise
agonist-stimulated fluid secretion in mice lacking caveolin1. J
Cell Sci. 2013;126(Pt 2):667–675.
[38] Resing KA, Meyer-Arendt K, Mendoza AM, Aveline-Wolf LD,
et al. Improving reproducibility and sensitivity in identifying
human proteins by shotgun proteomics. Anal Chem. 2004;
76(13):3556–3568.
[39] Liu X, Singh BB, Ambudkar IS. ATP-dependent activation of
KCa and ROMK-type KATP channels in human submandibular
gland ductal cells. J Biol Chem. 1999;274(35):25121–25129.
[40] Singh BB, Zheng C, Liu X, et al. Trp1-dependent enhancement
of salivary gland fluid secretion: role of store-operated calcium
entry. FASEB J. 2001;15(9):1652–1654.
[41] Baylin SB, Ohm JE. Ohm Epigenetic gene silencing in cancer -
a mechanism for early oncogenic pathway addiction? Nat Rev
Cancer. 2006;6(2):107–116.
[42] Ehlers MR. Immune-modulating effects of alpha-1 antitrypsin.
Biol Chem. 2014;395(10):1187–1193.
[43] Huber-Lang M, Ekdahl KN, Wiegner R, et al. Auxiliary activa-
tion of the complement system and its importance for the
pathophysiology of clinical conditions. Semin Immunopathol.
2018;40(1):87–102.
[44] Arvaniti P, Le Dantec C, Charras A, et al. Linking genetic vari-
ation with epigenetic profiles in Sj€ogren’s syndrome. Clin
Immunol. 2020;210:108314.
[45] Imgenberg-Kreuz J, Alml€of JC, Leonard D, et al. Shared and
unique patterns of DNA methylation in systemic lupus erythe-
matosus and primary Sj€ogren’s syndrome. Front Immunol.
2019;10:1686.
[46] Aslani S, Mahmoudi M, Karami J, et al. Epigenetic alterations
underlying autoimmune diseases. Autoimmunity. 2016;49(2):
69–83.
[47] Nayar G, Gauna A, Chukkapalli S, et al. Polymicrobial infection
alter inflammatory microRNA in rat salivary glands during
periodontal disease. Anaerobe. 2016;38:70–75.
[48] Hassan T, Carroll TP, Buckley PG, et al. miR-199a-5p silencing
regulates the unfolded protein response in chronic obstructive
pulmonary disease and a1-antitrypsin deficiency. Am J Respir
Crit Care Med. 2014;189(3):263–273.
282 B. B. SINGH ET AL.
